Correction: Clinical and Translational Oncology (2023) 25:2647–2664 https://doi.org/10.1007/s12094-023-03215-4


In Fig. 3 of this article, the second level of options appears “pT2, pT3 and/or pN ≥ 1” but it should have been “cT2, cT3 and/or cN ≥ 1”. In the last text box, the duration of Olaparib in BRCAmut should be 1 year instead of 2 years. The corrected figure is given below.

Fig. 3
figure 3

Triple negative early breast cancer algorithm. CT: chemotherapy. pCR: pathologic complete response


The original article has been corrected.